Precision Oncology is a medical and engineering challenge.
We support care teams and workflows for translational cancer treatments.
Appropriate Precision Oncology workflows reduce costs and make effective treatments available to more patients, sooner!
Idealized Precision Oncology workflows:
1: Start with Liquid Biopsy early detection.
2: Proceed with precision treatment matched to each individual's cancer's specific characteristics.
3: Succeed by sharing N of 1 treatment reports with follow-up Minimal Residual Disease surveillance.
Legacy medical methodology researches and treats cancer as a medical condition. With the onset of precision cancer antigen targeting, and other drug interventions the successful treatment of cancer is becoming more of a bio-engineering, data engineering and care coordination opportunity.
Sanguia recommends: CancerCommons.org
More efficient Lab- to-clinic processes save lives and reduce costs. Wider geographic reach increases the number of Patients treated and research data gathered.
The FDA is evolving to adapt to the special requirements of Precision Oncology with streamlined Genomic drug approval procedures.
Give your best care to more patients, now.
Patients benefit from their Primary Care Provider's online orchestration of best-available precision Oncology treatments when specialist advisory teams and appropriate drugs are coordinated.
Features Include:
+ Easy HIPAA compliant online care team collaboration spaces.
+ Asynchronous Chat or real-time televideo care team consultation capabilities.
+ Enhanced ICD-10 genomic data and valuable FHIR datasharing.
+ Templates for geographically dispersed clinical trials databases
Accelerating effective treatment roll-out
Life-saving care team and workflow tools
+ Earlier liquid biopsy detection
+ Faster genomic cancer characterization
+ Connecting geographically dispersed Patients and PCPs with appropriate researchers
+ Enabling effective precision translational treatment care.
+ Sharing treatment successes to promote more research
+ Minimal Residual Disease surveillance follow-up validating new treatments
➡️ Accelerating mainstreaming of faster validation and treatment.
Medicare will now reimburse next generation sequencing under some circumstances.
We consult on efficient precision oncology workflows and genomically -tuned pharma manufacturing. Robotic gripper adaptations, QR tracking and logging, and wet lab and CLIA management system integrations. Scaled up sequencing. Nuclear medicine pharmacy and production expertise.
Improve biopsy and treatment logistics.
The FDA must work to speed up the drug approval process, challenging the notion that new treatments must take over a decade to reach the market.
phylo.bio launches with $13.5 million seed round from Andreeson.
Drawn by high demand and Medicare reimbursement rules that reward expensive drugs and procedures, private equity firms have acquired hundreds of oncology practices nationwide.